



HAL
open science

Long-term outcomes after NeuroCOVID: A 6-month follow-up study on 60 patients

Hugo Chaumont, E. Meppiel, E. Roze, B. Tressières, T. de Broucker, A. Lannuzel

► **To cite this version:**

Hugo Chaumont, E. Meppiel, E. Roze, B. Tressières, T. de Broucker, et al.. Long-term outcomes after NeuroCOVID: A 6-month follow-up study on 60 patients. *Revue Neurologique*, 2022, 178 (1-2), pp.137-143. 10.1016/j.neurol.2021.12.008 . hal-04573166

HAL Id: hal-04573166

<https://hal.sorbonne-universite.fr/hal-04573166>

Submitted on 13 May 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Long-term outcomes after NeuroCOVID: a 6-month follow-up study on 60 patients

H. Chaumont^{a,b,c}, E. Meppiel^d, E. Roze^{c,e}, B. Tressières^f, T. de Broucker^d, A. Lannuzel^{a,b,c,f}, on behalf of the contributors to the French NeuroCOVID registry*

^a*Centre Hospitalier Universitaire de la Guadeloupe, Service de Neurologie, Pointe-à-Pitre/Abymes, France*

^b*Faculté de Médecine de l'université des Antilles, Pointe-à-Pitre, France*

^c*Sorbonne Université, Institut National de la Santé et de la Recherche Médicale, U 1127, CNRS, Unité Mixte de Recherche (UMR) 7225, Institut du Cerveau, Paris, France*

^d*Centre Hospitalier de Saint-Denis, Hôpital Delafontaine, Service de Neurologie, Saint-Denis, France*

^e*AP-HP, Hôpital de la Pitié-Salpêtrière, Département de Neurologie, Paris, France*

^f*Centre d'investigation Clinique Antilles Guyane, Inserm CIC 1424, Pointe-à-Pitre, France*

Corresponding author: Hugo Chaumont, MD, Department of Neurology, University Hospital of Guadeloupe, 97139, Pointe-à-Pitre/Abymes, French West Indies, France. Tel: +590 590 891 430; Fax number: +590 590 891 431; E-Mail: hugo.chaumont@chu-guadeloupe.fr

*Contributors to the French NeuroCOVID registry are listed to Supplementary Table S1.

Declaration of interests

H. Chaumont: received travel grants from PEPS development, Roche and Pfizer. E. Roze: served on scientific advisory boards for Orkyn, Aguetant, Merz-Pharma; received honoraria for speeches from Orkyn, Aguetant, Merz-Pharma, Medday-Pharma, Everpharma, International Parkinson and Movement disorders Society; received research support from Merz-Pharma, Orkyn, Aguetant, Elivie, Ipsen, Everpharma, Fondation Desmarest, AMADYS, Fonds de Dotation Brou de Laurière, Agence Nationale de la Recherche; received travel grant from Vitalair, PEPS development, Aguetant, Merz-Pharma, Ipsen, Merck, Orkyn, Elivie, Adelia Medical, Dystonia Medical Research Foundation, International Parkinson and Movement disorders Society, European Academy of Neurology, International Association of Parkinsonism and Related Disorders. A. Lannuzel: received research support from France Parkinson, PSP France, Agence Nationale de la Recherche, Fonds européen de développement regional, French Ministry of Health, University Hospital of Guadeloupe; received honoraria from Association des Neurologues du Québec and travel grants from Vitalair, PEPS development, Merz-Pharma, International Parkinson and Movement disorders Society. E. Meppiel, B. Tressières, and T. de Broucker have nothing to declare.

Abstract

Background and purpose: Long-term outcomes after neurological manifestations due to COVID-19 are poorly known. The aim of our study was to evaluate the functional outcome and identify the risk factors of neurologic sequelae after COVID-19 associated with neurological manifestations (NeuroCOVID).

Methods: We conducted a multi-center observational study six months after the acute neurological symptoms in patients from the French NeuroCOVID hospital-based registry.

Results: We obtained data on 60 patients. NeuroCOVID had a negative impact on the quality of life (QoL) of 49% of patients. Age was a predictor of residual QoL impairment (OR: 1.06, 95% CI: 1.01 – 1.13, $p = 0.026$). At six months, a significant residual disability was found in 51.7% of patients, and impaired cognition in 68.9% of cases. The main persistent neuropsychiatric manifestations were a persistent smell/taste disorder in 45% of patients, memory complaints in 34% of patients, anxiety or depression in 32% of patients.

Conclusions: NeuroCOVID likely carries a high risk of long-term neuropsychiatric disability. Long-term care and special attention should be given to COVID-19 patients, especially if they had neurological manifestations during acute infection.

Keywords: COVID-19, Neurological manifestation, NeuroCOVID, Post-COVID Syndrome, Long-term outcomes.

1. Introduction

SARS-CoV-2 infection is characterized by many persistent symptoms or sequelae known beyond two months after the acute phase of mild to severe COVID-19 [1,2]. Six months after acute infection, 76% of hospital-discharged patients reported persistent symptoms [3]. The most common symptoms are fatigue, muscle weakness, sleep difficulties [3], post-exertional malaise [4], and cognitive dysfunction [4,5]. Patients have an increased risk of mood and anxiety disorders within three months after COVID-19 infection [6]. The 6-month prevalence of self-reported olfactory dysfunction was evaluated at 60% in mild symptomatic COVID-19 patients [7].

During the acute phase of COVID-19, up to 36% of patients develop neurological manifestations [8]. Typically they consist of mild or nonspecific neurological symptoms such as confusion, dizziness, headache, and myalgia [8]. Less common severe diseases such as encephalopathy, encephalitis, stroke, Guillain-Barre syndrome, cranial nerves palsy, acute cerebellar ataxia, myoclonus, and mixed neurological disorders may also occur [9–15]. The long-term outcome of patients with neurological manifestations related to SARS-CoV-2 (NeuroCOVID) is poorly known.

To evaluate functional outcomes and identify risk factors of sequelae after COVID-19 associated with neurological manifestations, we conducted a multicenter observational study six months after the acute neurological episode in patients from the French NeuroCOVID multicenter registry [16].

2. Methods

2.1. Patients and Study Design

We included patients from the multicenter registry of 222 adult patients admitted for neurological manifestations associated with COVID-19. In this hospital-based study established during the first French epidemic wave in March and April 2020 [16], patients were considered to have NeuroCOVID in the presence of *de novo* neurological manifestations occurring five days before to 35 days after the first symptoms of COVID-19. The diagnosis of COVID-19 required either a positive SARS-CoV-2 real-time reverse transcriptase PCR assay result on a nasopharyngeal sample or typical clinical history and chest computed tomographic scan. The illness was classified as mild, moderate, severe, and critical according to the United States National Institutes of Health criteria [17]. Mild Illness for any infectious signs and symptoms of COVID-19 but no shortness of breath, dyspnea, or abnormal chest imaging; Moderate Illness for respiratory clinical or radiological involvement with saturation of oxygen (SpO₂) ≥ 94% on room air; Severe Illness for SpO₂ < 94% on room

air, ratio of arterial partial pressure of oxygen to fraction of inspired oxygen ($\text{PaO}_2/\text{FiO}_2$) < 300 mm Hg, respiratory frequency > 30 breaths/min, or lung infiltrates > 50%; Critical Illness for respiratory failure, septic shock, and/or multiple organ dysfunction. Neurologic manifestations were classified as either involving the central nervous system (CNS) or peripheral nervous system (PNS): encephalopathy (38.3%), stroke (28.4%), encephalitis and meningitis (10.9%), other CNS (7.7%), Guillain-Barre syndrome (6.8%), other PNS (9%) and mixed CNS and PNS (5.9%). Anosmia (3.2%) and ageusia (1.8%) were certainly underestimated as they may have been considered minor manifestations and, as such, not consistently recognized as neurological manifestations. All centers involved in this registry were contacted to participate in the follow-up study. Patients who died during the acute phase of COVID-19 and those followed in centers that declined their participation were not included. Six months after the onset of neurological signs, clinical assessment was scheduled during a telephone interview or by routine medical advice. The study was approved by the French Ile de France VIII ethic committee (2020-A01882-37).

2.2. Data collection and neurological investigations

We collected the following data: age, sex, clinical characteristics of COVID-19 defined in the multicenter registry (illness severity, neurological comorbidities, type, and chronology of neurologic manifestations). The severity of disability was graded using the modified Rankin Scale (mRS) [18]. Long-term residual disability was defined as mRS \geq 2 (level 2 corresponding to a slight disability, able to look after own affairs without assistance, but unable to carry out all previous activities). The 3-level version of the EuroQol five-dimension scale (EQ-5D-3L) was used to measure the quality of life [19]. EQ-5D-3L consists of five questions and a health-related visual analogue scale (VAS). In these questions, the respondents are asked to rate their current health state on five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) into one of three levels (no problems (1), some problems (2) or a lot of problems (3)). The answers are transformed into a utility value, describing the respondent's health, where utility=0 equals death and utility=1 equals perfect health. For example, the answer pattern 11111 would result in an ideal health state (utility=1), whereas 33333 would result in the worst possible health state. Our study considers a significant alteration of the quality of life if more than one question is at least two points (example: 12211, 21112). The EQ-VAS records the patient's self-rated health on a vertical visual analogue scale where the endpoints are labeled "Best imaginable health state" and "Worst imaginable health state." The VAS is a quantitative measure of health outcome that reflects the patient's judgment. Evaluation of cognition and mood included Montreal Cognitive Assessment Blind [20] (MoCA-Blind), 35-item version of Cognitive Difficulties Scale (CDS) [21], and Hospital Anxiety and Depression Scale (HADS) [22].

The MoCA-Blind is a version of the MoCA test without the visual elements (first four items). This score evaluates memory, attention, language, abstraction, delayed recall, and orientation. Scoring ranges from 0 to 22, with higher scores indicating better performance. A persistent cognitive dysfunction is defined by a MoCA-Blind score < 19 . The 35-item version of CDS is used to assess memory complaints et was considered abnormal if ≥ 15 . HADS is a 14-item inventory: seven to evaluate depression and seven to assess anxiety. Each item scores 0-3. After summing up scores, a total score of 0-7 was taken as “no depression/anxiety”, 8-10 was taken as “moderate depression/anxiety”, and 11-21 was taken as “severe depression/anxiety”. Taste and Smell Survey (TSS) [23] was used to detect persistent olfactory or gustatory dysfunction. Persistent olfactory or gustatory dysfunction was present if the olfactory score or gustatory score were ≥ 1 .

2.3. Statistical analysis

Quantitative variables were summarized as median with interquartile range (IQR) and compared across groups using the Wilcoxon test. Categorical data were expressed as a percentage and compared between groups using the Chi-square test or Fisher exact test, depending on the sample size. Logistic regression models were used to identify factors associated with long-term residual disability, significant alteration of the quality of life, memory complaints, persistent cognitive dysfunction, moderate or severe depression/anxiety, and persistent olfactory or gustatory dysfunction. Factors investigated were the demographic characteristics, neurologic comorbidities, types of neurological manifestations, occurrence of neurologic manifestations relative to COVID-19 symptoms, neurological symptoms, and severity of COVID-19. All statistical analyses were performed using R 4.0.2, and significance was considered at the level 5%.

2.4. Data availability

Some data will be made available from the corresponding author, upon reasonable request. The data are not publicly available because they contain information that could compromise the privacy of our patients.

3. Results

Sixty patients among the 194 who survived a confirmed diagnosis of COVID-19 were included in this study performed within a median of 6 months (IQR 6-7) after the acute phase of NeuroCOVID (Fig 1). Fifty patients (83.3%) had central nervous system (CNS) involvement, five (8.3%) had peripheral nervous system (PNS) disorder. For five of them (8.3%), the mechanism was undetermined (Table 1). Twenty-six patients (43.3%) had a severe or critical NeuroCOVID and ten (16.7%) had a history of neurological comorbidities :

stroke (n = 3), neurodegenerative disorder (n = 3), epilepsy (n = 2), sequels of Guillain-Barre syndrome (n = 1), axonal sensitive neuropathy (n = 1). No difference was observed in patients' demographic and neurological characteristics included in the follow-up study than those from the initial registry (Supplementary Table S2). The follow-up was done by phone interview (n = 49) or during a medical visit (n = 11). Results are shown in Table 2.

Of the 60 patients, 31 (51.7%) had a residual disability (mRS \geq 2). Slight disability (mRS = 2) was found in ten patients (16.7%) who were able to look after their affairs without assistance but unable to carry out all previous activities. Disability was moderate in 11 patients (18.3%) (mRS = 3). These patients required some help but able to walk without assistance. Ten (16.6%) had a severe residual disability, two of them (3%, mRS = 4) were unable to walk without assistance and unable to attend to their own bodily needs without assistance, and eight (13.3%, mRS = 5) were bedridden and required constant nursing care and attention. Severely disabled patients could not perform tests or questionnaires concerning the quality of life, memory complaints, cognitive and sensory deficit. NeuroCOVID had a negative impact on the quality of life in 49% of cases (25/51 patients). The most altered sub-scores were mobility, with 35% of patients reporting having problems walking, and pain with 43% having moderate pain and 15% severe pain. Thirty-four percent (17/50 patients) had residual memory complaints. The MoCA-Blind score was abnormal (< 19/30) in 68.9% of cases (31/45 patients). Fourteen patients (28%, 14/50 patients) had anxiety symptoms, and eight patients (16%, 8/50 patients) reported symptoms of depression. Overall, 32% (16/50 patients) presented at least one symptom of anxiety or depression. Smell or taste persistent disorder was found in twenty-three patients (45%, 23/51 patients) six months after NeuroCOVID.

In multivariate analysis, age was found as a risk factor of impaired quality of life (OR 1.06 per year, 95% CI 1.01, 1.13, $P = 0.026$). Neither age, sex, neurological comorbidities, the severity of COVID-19, type of neurological manifestation was associated with residual disability, cognitive impairment, depression or anxiety, or the presence of a sensory deficit.

4. Discussion

Our study describes the long-term course of NeuroCOVID. Half of our patients had residual disability and impaired quality of life six months after the acute phase. Cognitive difficulties, anxious and depressive symptoms, and smell/taste disorders were the most frequent neuropsychiatric sequelae. Interestingly, we found that age predicts the long-term alteration of QoL after NeuroCOVID. This emphasizes the need for special attention and long-term care over months in patients with NeuroCOVID, particularly in the oldest patients.

Our study has limitations. First, the retrospective nature of the study puts at risk the possibility of recall bias. Second, many patients from the registry refuse to answer the phone

interview, introducing a bias of selection. The study group was comparable to the registered population (Supplementary Table), which partially limits this bias. The relatively small number of patients could also have led to a lack of statistical power. Additionally, in the absence of a control group of COVID patients with no neurological manifestation, we cannot definitively distinguish the impact of neurological involvement from the consequences of COVID in other organs and functions. Lastly, the lack of comprehensive information on the premorbid functional status of our patients could represent another difficulty for results interpretation.

Half of our patients (49%) reported an alteration of their QoL six months after discharge. It is consistent with the findings of a previous 6-month follow-up studies in older COVID-19 patients with or without neurological involvement (median 74 years versus 66 years in our study) discharged from hospital [24]. Age is reported as a predictor of residual impaired quality of life in a previous 3-month follow-up study of COVID-19 patients [25]. In some COVID-19 series, patients are primarily classified according to the severity of the disease without detailed information about specific involvement of various organs, including nervous system [24–26]. The long-term consequences of neurological impairment on the QoL could be drowned in those of severe overall impairment. In our younger population, a significant recovery of the worsening of the neurological symptoms within six months after the acute phase, a lack of control group, or a lack of statistical power could have prevented us to detect a potential impact of neurological damage on the alteration in the quality of life.

In our study, preexisting neurological comorbidities, reported in 17% of patients, were not statistically related to a poor neuropsychiatric outcome at six months. In retrospective COVID-19 hospital-based cohort studies, preexisting neurological diseases were found as an independent risk factor for poor outcomes during the acute phase [27,28] and at discharge [29–31]. Furthermore, worsening of preexisting neurological conditions was frequently observed immediately after a COVID-19 [30–32]. A significant recovery of the worsening of the neurological comorbidity six months after the acute phase or a lack of statistical power could explain this discordant result in our study.

Anxiety and depression were present six months after discharge in 10-31% in cohort studies of COVID-19 patients [3,5,33], and in 25-46% in a recent prospective study among hospitalized COVID-19 patients with neurological complications [34]. These symptoms were detected in the same proportion in our study (32%), and no risk factors were identified. The severity of COVID-19 disease was previously identified as a risk factor for developing anxiety disorders [3]. It was not found in our study (43% with severe or critical disease), possibly due to the lack of statistical power.

Persistent cognitive impairment ranged from 36% and 65% of COVID-19 patients three/four months after discharge [5,33,35], and in 50% of patients with neurological complications of COVID-19 during the index hospitalization [34]. The higher proportion in our

study (68.9%) could be explained by the use of various cognitive tests. Critically ill patients are known to have a risk of developing cognitive impairment 12 months after discharge due to a longer duration of delirium (mainly sedative-associated-delirium), sepsis, hypoxemia, and doses of sedatives [36]. This condition explains a part of persistence of cognitive impairment in 43% of our patients but is probably not the only cause of this condition since around 60% of patients had persistent cognitive disorders after seven months, even in mild COVID-19 [4]. Prolonged systemic inflammation might predispose to persistent depression and associated neurocognitive dysfunction [37]. Whether prolonged cognitive impairment might be related to pathological changes associated with critical illness-related encephalopathy or specific to SARS-CoV-2 infection remains unclarified. Retrograde neuroinvasion from the olfactory sensory neurons to their downstream brain structures is likely to be involved in selective neurological damage related to SARS-CoV-2 infection [38]. Other possible gateways to the CNS comprise the blood-brain barrier epithelium and brain infiltration by peripheral immune cells [38].

Loss of smell or taste is a frequent symptom of acute COVID-19 [39,40]. Various non-exclusive pathogenic mechanisms can account for these manifestations, namely obstruction of the olfactory cleft [41], perturbation of supporting cells of the olfactory epithelium [42], alteration of olfactory sensory neurons neurogenesis [43], and secondary neurological damage related to edema in the olfactory bulb [44,45]. A recent study indicates that olfactory neuroepithelium is an important site of SARS-CoV-2 infection and that SARS-CoV-2 persistence and related inflammation likely account for the prolonged loss of smell in patients [38]. When detected by a specific questionnaire, olfactory dysfunction was found in 51.3% of mild symptomatic COVID-19 patients one month after the acute phase [46] and 60% after six months [7], which is closed to our result (45%) after six months. The balance of patients with smell or taste sequelae is lower (between 10 and 20%) when patients are simply asked about the presence of smell or taste symptoms [47,48].

NeuroCOVID likely carries a risk of long-term neuropsychiatric disability. Further NeuroCOVID cohort studies using control groups are needed to assess specific long-term outcomes of neurological manifestations associated with COVID-19 infection and clarify their pathogenesis.

Disclosure of interest

H. Chaumont: received travel grants from PEPS development, Roche and Pfizer. E. Roze: served on scientific advisory boards for Orkyn, Aguetant, Merz-Pharma; received honoraria for speeches from Orkyn, Aguetant, Merz-Pharma, Medday-Pharma, Everpharma, International Parkinson and Movement disorders Society; received research support from

Merz-Pharma, Orkyn, Aguetant, Elivie, Ipsen, Everpharma, Fondation Desmarest, AMADYS, Fonds de Dotation Brou de Laurière, Agence Nationale de la Recherche; received travel grant from Vitalair, PEPS development, Aguetant, Merz-Pharma, Ipsen, Merck, Orkyn, Elivie, Adelia Medical, Dystonia Medical Research Foundation, International Parkinson and Movement disorders Society, European Academy of Neurology, International Association of Parkinsonism and Related Disorders. A. Lannuzel: received research support from France Parkinson, PSP France, Agence Nationale de la Recherche, Fonds européen de développement regional, French Ministry of Health, University Hospital of Guadeloupe; received honoraria from Association des Neurologues du Québec and travel grants from Vitalair, PEPS development, Merz-Pharma, International Parkinson and Movement disorders Society. E. Meppiel, B. Tressières, and T. de Broucker have nothing to declare.

References

- [1] Carfi A, Bernabei R, Landi F, for the Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent Symptoms in Patients After Acute COVID-19. *JAMA* 2020;324:603. <https://doi.org/10.1001/jama.2020.12603>.
- [2] Halpin SJ, McIvor C, Whyatt G, Adams A, Harvey O, McLean L, et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation. *J Med Virol* 2021;93:1013–22. <https://doi.org/10.1002/jmv.26368>.
- [3] Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. *The Lancet* 2021;0. [https://doi.org/10.1016/S0140-6736\(20\)32656-8](https://doi.org/10.1016/S0140-6736(20)32656-8).
- [4] Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re'em Y, et al. Characterizing Long COVID in an International Cohort: 7 Months of Symptoms and Their Impact. *MedRxiv* 2020:2020.12.24.20248802. <https://doi.org/10.1101/2020.12.24.20248802>.
- [5] The Writing Committee for the COMEBAC Study Group, Morin L, Savale L, Pham T, Colle R, Figueiredo S, et al. Four-Month Clinical Status of a Cohort of Patients After Hospitalization for COVID-19. *JAMA* 2021;325:1525. <https://doi.org/10.1001/jama.2021.3331>.
- [6] Taquet M, Luciano S, Geddes JR, Harrison PJ. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. *The Lancet Psychiatry* 2020;0. [https://doi.org/10.1016/S2215-0366\(20\)30462-4](https://doi.org/10.1016/S2215-0366(20)30462-4).
- [7] Boscolo-Rizzo P, Menegaldo A, Fabbris C, Spinato G, Borsetto D, Vaira LA, et al. Six-month psychophysical evaluation of olfactory dysfunction in patients with COVID-19. *Chemical Senses* 2021:bjab006. <https://doi.org/10.1093/chemse/bjab006>.
- [8] Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. *JAMA Neurol* 2020;77:683. <https://doi.org/10.1001/jamaneurol.2020.1127>.
- [9] Moriguchi T, Harii N, Goto J, Harada D, Sugawara H, Takamino J, et al. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. *International Journal of Infectious Diseases* 2020;94:55–8. <https://doi.org/10.1016/j.ijid.2020.03.062>.
- [10] Poyiadji N, Shahin G, Noujaim D, Stone M, Patel S, Griffith B. COVID-19–associated Acute Hemorrhagic Necrotizing Encephalopathy: Imaging Features. *Radiology* 2020;296:E119–20. <https://doi.org/10.1148/radiol.2020201187>.
- [11] Oxley TJ, Mocco J, Majidi S, Kellner CP, Shoirah H, Singh IP, et al. Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young. *N Engl J Med* 2020;382:e60. <https://doi.org/10.1056/NEJMc2009787>.
- [12] Dinkin M, Gao V, Kahan J, Bobker S, Simonetto M, Wechsler P, et al. COVID-19 presenting with ophthalmoparesis from cranial nerve palsy. *Neurology* 2020;95:221–3. <https://doi.org/10.1212/WNL.0000000000009700>.
- [13] Toscano G, Palmerini F, Ravaglia S, Ruiz L, Invernizzi P, Cuzzoni MG, et al. Guillain–Barré Syndrome Associated with SARS-CoV-2. *N Engl J Med* 2020;382:2574–6. <https://doi.org/10.1056/NEJMc2009191>.

- [14] Foucard C, San-Galli A, Tarrano C, Chaumont H, Lannuzel A, Roze E. Acute cerebellar ataxia and myoclonus with or without opsoclonus: a parainfectious syndrome associated with COVID-19. *European Journal of Neurology* 2021;ene.14726. <https://doi.org/10.1111/ene.14726>.
- [15] Chaumont H, San-Galli A, Martino F, Couratier C, Jogue G, Carles M, et al. Mixed central and peripheral nervous system disorders in severe SARS-CoV-2 infection. *J Neurol* 2020;267:3121–7. <https://doi.org/10.1007/s00415-020-09986-y>.
- [16] Meppiel E, Peiffer-Smadja N, Maury A, Bekri I, Delorme C, Desestret V, et al. Neurologic manifestations associated with COVID-19: a multicentre registry. *Clinical Microbiology and Infection* 2020:S1198743X20306984. <https://doi.org/10.1016/j.cmi.2020.11.005>.
- [17] COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at <https://www.covid19treatmentguidelines.nih.gov/>. Accessed [insert date]. n.d.
- [18] Bamford JM, Sandercock PA, Warlow CP, Slattery J. Interobserver agreement for the assessment of handicap in stroke patients. *Stroke* 1989;20:828–828. <https://doi.org/10.1161/01.STR.20.6.828>.
- [19] Rabin R, Charro F de. EQ-SD: a measure of health status from the EuroQol Group. *Annals of Medicine* 2001;33:337–43. <https://doi.org/10.3109/07853890109002087>.
- [20] Nasreddine ZS, Phillips NA, BÃ©dirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment: MOCA: A BRIEF SCREENING TOOL FOR MCI. *Journal of the American Geriatrics Society* 2005;53:695–9. <https://doi.org/10.1111/j.1532-5415.2005.53221.x>.
- [21] McNair D, Kahn R. Self assessment of cognitive deficits. 1984.
- [22] Zigmond A, Snaith R. The Hospital Anxiety and Depression Scale. 1983.
- [23] Heald AE, Pieper CF, Schiffman SS. Taste and smell complaints in HIV-infected patients: *AIDS* 1998;12:1667–74. <https://doi.org/10.1097/00002030-199813000-00015>.
- [24] Walle-Hansen MM, Ranhoff AH, Mellingsæter M, Wang-Hansen MS, Myrstad M. Health-related quality of life, functional decline, and long-term mortality in older patients following hospitalisation due to COVID-19. *BMC Geriatr* 2021;21:199. <https://doi.org/10.1186/s12877-021-02140-x>.
- [25] Qu G, Zhen Q, Wang W, Fan S, Wu Q, Zhang C, et al. Health-related quality of life of COVID-19 patients after discharge: A multicenter follow-up study. *J Clin Nurs* 2021;jocn.15733. <https://doi.org/10.1111/jocn.15733>.
- [26] Gautam N, Madathil S, Tahani N, Bolton S, Parekh D, Stockley J, et al. Medium-term outcome of severe to critically ill patients with SARS-CoV-2 infection. *Clinical Infectious Diseases* 2021:ciab341. <https://doi.org/10.1093/cid/ciab341>.
- [27] Benussi A, Pilotto A, Premi E, Libri I, Giunta M, Agosti C, et al. Clinical characteristics and outcomes of inpatients with neurologic disease and COVID-19 in Brescia, Lombardy, Italy. *Neurology* 2020;95:e910–20. <https://doi.org/10.1212/WNL.0000000000009848>.
- [28] Livingston G, Rostampour H, Gallagher P, Kalafatis C, Shastri A, Huzzey L, et al. Prevalence, management, and outcomes of SARS-CoV-2 infections in older people and those with dementia in

mental health wards in London, UK: a retrospective observational study. *The Lancet Psychiatry* 2020;7:1054–63. [https://doi.org/10.1016/S2215-0366\(20\)30434-X](https://doi.org/10.1016/S2215-0366(20)30434-X).

[29] Qin C, Zhou L, Hu Z, Yang S, Zhang S, Chen M, et al. Clinical Characteristics and Outcomes of COVID-19 Patients With a History of Stroke in Wuhan, China. *Stroke* 2020;51:2219–23. <https://doi.org/10.1161/STROKEAHA.120.030365>.

[30] Bianchetti A, Rozzini R, Guerini F, Boffelli S, Ranieri P, Minelli G, et al. Clinical Presentation of COVID19 in Dementia Patients. *J Nutr Health Aging* 2020;24:560–2. <https://doi.org/10.1007/s12603-020-1389-1>.

[31] Ji W, Huh K, Kang M, Hong J, Bae GH, Lee R, et al. Effect of Underlying Comorbidities on the Infection and Severity of COVID-19 in Korea: a Nationwide Case-Control Study. *J Korean Med Sci* 2020;35:e237. <https://doi.org/10.3346/jkms.2020.35.e237>.

[32] Antonini A, Leta V, Teo J, Chaudhuri KR. Outcome of Parkinson's Disease Patients Affected by COVID -19. *Mov Disord* 2020;35:905–8. <https://doi.org/10.1002/mds.28104>.

[33] van den Borst B, Peters JB, Brink M, Schoon Y, Bleeker-Rovers CP, Schers H, et al. Comprehensive health assessment three months after recovery from acute COVID-19. *Clinical Infectious Diseases* 2020:ciaa1750. <https://doi.org/10.1093/cid/ciaa1750>.

[34] Frontera JA, Yang D, Lewis A, Patel P, Medicherla C, Arena V, et al. A prospective study of long-term outcomes among hospitalized COVID-19 patients with and without neurological complications. *Journal of the Neurological Sciences* 2021;426:117486. <https://doi.org/10.1016/j.jns.2021.117486>.

[35] Miskowiak K, Johnsen S, Sattler S, Nielsen S, Kunalan K, Rungby J, et al. Cognitive impairments four months after COVID-19 hospital discharge: Pattern, severity and association with illness variables. *European Neuropsychopharmacology* 2021;46:39–48. <https://doi.org/10.1016/j.euroneuro.2021.03.019>.

[36] Girard TD, Thompson JL, Pandharipande PP, Brummel NE, Jackson JC, Patel MB, et al. Clinical phenotypes of delirium during critical illness and severity of subsequent long-term cognitive impairment: a prospective cohort study. *The Lancet Respiratory Medicine* 2018;6:213–22. [https://doi.org/10.1016/S2213-2600\(18\)30062-6](https://doi.org/10.1016/S2213-2600(18)30062-6).

[37] Mazza MG, Palladini M, De Lorenzo R, Magnaghi C, Poletti S, Furlan R, et al. Persistent psychopathology and neurocognitive impairment in COVID-19 survivors: Effect of inflammatory biomarkers at three-month follow-up. *Brain, Behavior, and Immunity* 2021;94:138–47. <https://doi.org/10.1016/j.bbi.2021.02.021>.

[38] de Melo GD, Lazarini F, Levallois S, Hautefort C, Michel V, Larrous F, et al. COVID-19-related anosmia is associated with viral persistence and inflammation in human olfactory epithelium and brain infection in hamsters. *Sci Transl Med* 2021:eabf8396. <https://doi.org/10.1126/scitranslmed.abf8396>.

[39] Xydakis MS, Dehgani-Mobaraki P, Holbrook EH, Geisthoff UW, Bauer C, Hautefort C, et al. Smell and taste dysfunction in patients with COVID-19. *The Lancet Infectious Diseases* 2020;20:1015–6. [https://doi.org/10.1016/S1473-3099\(20\)30293-0](https://doi.org/10.1016/S1473-3099(20)30293-0).

[40] Qiu C, Cui C, Hautefort C, Haehner A, Zhao J, Yao Q, et al. Olfactory and Gustatory Dysfunction as an Early Identifier of COVID-19 in Adults and Children: An International Multicenter Study. *Otolaryngol Head Neck Surg* 2020;163:714–21. <https://doi.org/10.1177/0194599820934376>.

- [41] Eliezer M, Hamel A-L, Houdart E, Herman P, Housset J, Jourdain C, et al. Loss of smell in patients with COVID-19: MRI data reveal a transient edema of the olfactory clefts. *Neurology* 2020;95:e3145–52. <https://doi.org/10.1212/WNL.0000000000010806>.
- [42] Brann DH, Tsukahara T, Weinreb C, Lipovsek M, Van den Berge K, Gong B, et al. Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia. *SciAdv* 2020;6:eabc5801. <https://doi.org/10.1126/sciadv.abc5801>.
- [43] Saussez S, Lechien JR, Hopkins C. Anosmia: an evolution of our understanding of its importance in COVID-19 and what questions remain to be answered. *Eur Arch Otorhinolaryngol* 2020. <https://doi.org/10.1007/s00405-020-06285-0>.
- [44] Laurendon T, Radulesco T, Mugnier J, G erault M, Chagnaud C, El Ahmadi A-A, et al. Bilateral transient olfactory bulb edema during COVID-19–related anosmia. *Neurology* 2020;95:224–5. <https://doi.org/10.1212/WNL.0000000000009850>.
- [45] Arag o MFVV, Leal MC, Cartaxo Filho OQ, Fonseca TM, Valen a MM. Anosmia in COVID-19 Associated with Injury to the Olfactory Bulbs Evident on MRI. *AJNR Am J Neuroradiol* 2020;ajnr;ajnr.A6675v1. <https://doi.org/10.3174/ajnr.A6675>.
- [46] Boscolo-Rizzo P, Borsetto D, Fabbris C, Spinato G, Frezza D, Menegaldo A, et al. Evolution of Altered Sense of Smell or Taste in Patients With Mildly Symptomatic COVID-19. *JAMA Otolaryngol Head Neck Surg* 2020;146:729. <https://doi.org/10.1001/jamaoto.2020.1379>.
- [47] Paderno A, Mattavelli D, Rampinelli V, Grammatica A, Raffetti E, Tomasoni M, et al. Olfactory and Gustatory Outcomes in COVID-19: A Prospective Evaluation in Nonhospitalized Subjects. *Otolaryngol Head Neck Surg* 2020;163:1144–9. <https://doi.org/10.1177/0194599820939538>.
- [48] Petersen MS, Kristiansen MF, Hanusson KD, Danielsen ME,   Steig B, Gaini S, et al. Long COVID in the Faroe Islands - a longitudinal study among non-hospitalized patients. *Clinical Infectious Diseases* 2020. <https://doi.org/10.1093/cid/ciaa1792>.

Table 1 Demographic and neurological characteristics

At acute phase	n (%)
N	60
Age , median (IQR)	66 (55-73)
Male	36 (60.0%)
Neurological comorbidities	
No	50 (83.3%)
Yes ^{&}	10 (16.7%)
Severity of COVID-19	
Mild/Moderate	34 (56.7%)
Severe/Critical	26 (43.3%)
Neurological manifestations in the acute phase	
Stroke	18 (30.0%)
Encephalopathy	18 (30.0%)
Encephalitis-Meningitis	8 (13.3%)
Other CNS [‡]	6 (10.0%)
PNS [§]	5 (8.3%)
Undetermined mechanism	5 (8.3%)
Anosmia	4 (6.7%)
Ageusia	3 (5.0%)
Type of stroke	
Ischemic stroke	14 (23.3%)
Transient ischemic attack	3 (5.0%)
Intracerebral hemorrhage	1 (1.7%)
Cerebral venous thrombosis	0 (0%)

Abbreviations: IQR: Inter Quartile Range; CNS: central nervous system; PNS: peripheral nervous system.

[&]Stroke (n = 3), neurodegenerative disorder (n = 3), epilepsy (n = 2), others (n = 2).

[‡]Transient alteration of consciousness (n=3), isolated seizure (n=2), and generalized myoclonus with cerebellar ataxia (n=1).

[§]Peripheral complications of intensive care unit (n=2), Guillain-Barre syndrome (n=3).

TABLE 2 Characteristics of NeuroCOVID patients at the follow-up evaluation

	n/N	%	95% CI
Disability (mRS^a)			
Score - median (IQR)	2 (1-3)		
0-1	29/60	48.3	35.2 - 61.6
2-5	31/60	51.7	38.4 - 64.8
Quality of live (EQ-5D-3L^b)			
Not altered	26/51	51.0	36.6 - 65.2
Altered	25/51	49.0	34.8 - 63.4
Memory complain (CDS)			
Score - median (IQR)	11 (5-18)		
Normal (<15)	33/50	66.0	51.2 - 78.8
Abnormal (≥15)	17/50	34.0	21.2 - 48.8
Cognitive assessment (MoCA-Blind)			
Score - median (IQR)	17 (14-19)		
Normal (≥19)	14/45	31.1	18.2 - 46.6
Abnormal (<19)	31/45	68.9	53.4 - 81.8
Anxiety - Depression (HADS^c)			
Anxiety score - median (IQR)	5 (1-9)		
Depression score - median (IQR)	2 (1-6)		
Not altered	34/50	68.0	53.8 - 80.5
Altered	16/50	32.0	19.5 - 46.7
Taste and Smell Survey (TSS^d)			
Taste score - median (IQR)	0 (0-4)		
Smell score - median (IQR)	0 (0-3)		
Not altered	28/51	54.9	40.3 - 68.9
Altered	23/51	45.1	31.1 - 59.7

Abbreviations: 95% CI: 95% Confidence Interval; IQR: Inter Quartile Range; mRS: modified Rankin Scale; EQ-5D-3L: 3-level version of the EuroQol five-dimension scale; CDS: 35-item version of Cognitive Difficulties Scale; MoCA-Blind: Montreal Cognitive Assessment Blind; HADS : Hospital Anxiety and Depression Scale; TSS: Taste and Smell Survey.

^a 0: no symptoms at all; 1: no significant disability despite symptoms; able to carry out all usual duties and activities; 2: slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance; 3: moderate disability; requiring some help, but able to walk without assistance; 4: moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance; 5: severe disability; bedridden, incontinent and requiring constant nursing care and attention.

^b Significant alteration when more than one question is at least two points (example: 12211, 21112...).

^c Altered when at least one score, depression or anxiety was > 7 .

^d Altered when at least one score, taste or smell was ≥ 1 .

Figures Legends

Fig 1 Enrollment and outcome in the French NeuroCOVID multicenter registry

